Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H78O3 |
| Molecular Weight | 667.099 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H](C)CCCC(C)C
InChI
InChIKey=MEOFSGIGKMJGOJ-FTKDFQSGSA-N
InChI=1S/C45H78O3/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-42(47)48-37-28-30-44(5)36(32-37)33-41(46)43-39-27-26-38(35(4)24-22-23-34(2)3)45(39,6)31-29-40(43)44/h14-15,33-35,37-41,43,46H,7-13,16-32H2,1-6H3/b15-14-/t35-,37+,38-,39+,40+,41+,43+,44+,45-/m1/s1
7β-hydroxycholesteryl-3-oleate has been shown to inhibit astrogliosis and intracranial glioblastoma growth. Local administration of 7β-hydroxycholesteryl-3-oleate inhibits growth of experimental rat C6 glioblastoma. These data suggest that 7β-hydroxycholesteryl-3-oleate might be useful for local glioblastoma chemotherapy. 7β-hydroxycholesteryl-3-oleate is a potent inhibitor of the endogenous cholesterol biosynthesis in brain showing a correlation between cholesterogenesis and reactive astrocyte proliferation. 7β-hydroxycholesteryl-3-oleate can reduce the astrocytic reaction following spinal cord injury, promoting the serotonergic reinnervation of a denervated territory. On 17 December 2010, orphan designation (EU/3/10/816) was granted by the European Commission to Intsel Chimos SA, France, for 7-beta-hydroxy cholesteryl-3-beta-oleate for the treatment of glioma. The substance is going to be injected directly into the brain tumour contained within liposomes, which are expected to carry the medicine into the glioma cells.
Approval Year
Sample Use Guides
Wistar rats: Α midline skin incision was
made, and the skull was perforated using α dental drill 2 mm
right of the midline and 4.5 mm anterior to the lambda. Lesions were performed by lowering an epoxylite-coated
(except at the tip) stainless steel electrode 2.0 mm under
the skull surface and applying α 2-mA DC for 10 s. Treatment consisted of injection, in the lesion site, of 2 uΙ of α liposome suspension (containing 12 nmol of 7 beta-hydroxycholesteryl-3-oleate ) within 4 min using α Hamilton syringe
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
343511
Created by
admin on Sat Dec 16 04:55:37 GMT 2023 , Edited by admin on Sat Dec 16 04:55:37 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000183814
Created by
admin on Sat Dec 16 04:55:37 GMT 2023 , Edited by admin on Sat Dec 16 04:55:37 GMT 2023
|
PRIMARY | |||
|
EU/3/10/816(POSITIVE)
Created by
admin on Sat Dec 16 04:55:37 GMT 2023 , Edited by admin on Sat Dec 16 04:55:37 GMT 2023
|
PRIMARY | Treatment of glioma 17/12/2010 Positive | ||
|
141099-60-7
Created by
admin on Sat Dec 16 04:55:37 GMT 2023 , Edited by admin on Sat Dec 16 04:55:37 GMT 2023
|
PRIMARY | |||
|
A59FMD985O
Created by
admin on Sat Dec 16 04:55:37 GMT 2023 , Edited by admin on Sat Dec 16 04:55:37 GMT 2023
|
PRIMARY | |||
|
70179250
Created by
admin on Sat Dec 16 04:55:37 GMT 2023 , Edited by admin on Sat Dec 16 04:55:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
